Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.33USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$1.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
256,940
52-wk High
$1.72
52-wk Low
$1.03

Chart for

About

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)

Overall

Beta: 2.24
Market Cap(Mil.): $91.84
Shares Outstanding(Mil.): 69.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.91 16.25
EPS (TTM): -- -- --
ROI: -- 15.14 14.87
ROE: -- 16.37 13.89

BRIEF-Alimera Sciences ‍announces Iluvien now available in Ireland​

* Alimera Sciences Inc - ‍Announces Iluvien now available in Ireland​ Source text for Eikon: Further company coverage:

Sep 12 2017

BRIEF-Alimera Sciences signs agreement for distribution of Iluvien in France

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in France

Aug 29 2017

BRIEF-Alimera Sciences Q2 ‍net loss per share $0.04​

* Alimera Sciences reports second quarter 2017 financial results

Aug 02 2017

BRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment

* Alimera Sciences announces real-world audit data supporting the positive benefits of iluvien treatment

Jul 25 2017

BRIEF-Alimera Sciences announces italian patients now being treated with Iluvien

* Alimera Sciences announces italian patients now being treated with Iluvien® Source text for Eikon: Further company coverage:

Jul 12 2017

BRIEF-pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN

* pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN

Jul 10 2017

BRIEF-ALIMERA SCIENCES REPORTS Q1 LOSS PER SHARE $0.10

* ALIMERA SCIENCES REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS

May 08 2017

Earnings vs. Estimates